[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100656611":3},{"organization":4,"outcomesModule":7,"designInfo":23,"detailedDescription":30,"studyPopulation":26,"armGroups":31,"interventions":38,"overallOfficials":47,"centralContacts":52,"locations":58,"responsibleParty":76,"collaborators":26,"id":79,"slug":80,"hasResults":81,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":26,"eligibilityCriteria":85,"healthyVolunteers":81,"sex":86,"minAge":87,"maxAge":88,"enrollmentInfo":89,"targetDuration":26,"studyType":92,"phases":93,"briefSummary":95,"conditions":96,"keywords":98,"overallStatus":60,"whyStopped":26,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":112,"completionDateStruct":113,"leadSponsor":115,"locationsCount":116},{"fullName":5,"class":6},"Henry Ford Health System","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":18},[9],{"measure":10,"description":11,"timeFrame":12},"Detection of tumor fluorescence using 5-ALA under blue light","Surgeons will assess whether renal tumors exhibit visible fluorescence under blue light following oral administration of 5-ALA (20 mg\u002Fkg). The presence or absence of fluorescence will be recorded for each lesion during partial nephrectomy.","Intra-operatively",[14],{"measure":15,"description":16,"timeFrame":17},"Incidence and severity of adverse events following 5-ALA administration","Incidence and severity (Grade 1-5, CTCAE v5.0) of adverse events related to 5-ALA administration (e.g., hypotension, GI effects, liver enzyme elevation, photosensitivity)","Up to 30 days after intervention",[19],{"measure":20,"description":21,"timeFrame":22},"Final tumor pathology","Presence or absence of residual tumor after resection","Up to 2 weeks post-operatively",{"allocation":24,"interventionModel":25,"interventionModelDescription":26,"primaryPurpose":27,"observationalModel":26,"timePerspective":26,"maskingInfo":28},"NA","SINGLE_GROUP",null,"DIAGNOSTIC",{"masking":29,"maskingDescription":26,"whoMasked":26},"NONE","5-Aminolevulinic Acid (5-ALA), Gleolan, Kidney Cancer, Renal Cell Carcinoma, Partial Nephrectomy, Photodynamic Diagnosis (PDD), Fluorescence-Guided Surgery, Blue Light Imaging, Tumor Detection, Surgical Margins, Safety Profile, Adverse Events, Clinical Trial, Robotic Surgery, Pathology, Fluorescence Imaging, Renal Tumors, Pilot Study, Diagnostic Accuracy, Phase III Trial\n\nThis pilot clinical study aims to evaluate the safety and efficacy of 5-aminolevulinic acid (5-ALA; Gleolan) as a fluorescence-guided imaging agent for patients undergoing partial nephrectomy for suspected kidney cancer. Although 5-ALA is currently FDA-approved for visualization of high-grade gliomas during neurosurgery, emerging evidence suggests that it may also improve the detection of renal tumors through photodynamic diagnosis (PDD). The investigators hypothesize that oral administration of 5-ALA will cause kidney tumors to fluoresce under blue light, allowing surgeons to more easily identify tumors and assess resection margins while maintaining a favorable safety profile with minimal adverse events.\n\nThe study plans to enroll 10 adult patients aged 18 to 75 years who have kidney tumors amenable to standard-of-care partial nephrectomy. Eligible participants must have good performance status (ECOG 0-1) and adequate renal, hepatic, and hematologic function. Patients with significant cardiovascular disease, active liver disease, poorly controlled infections, pregnancy, porphyria-related hypersensitivity, or other major comorbidities will be excluded.\n\nAfter informed consent is obtained, patients will undergo baseline laboratory testing including a comprehensive metabolic panel (CMP), liver function tests, lactate dehydrogenase (LDH), and γ-glutamyl transferase (GGT). On the day of surgery, participants will receive 20 mg\u002Fkg of oral 5-ALA dissolved in water approximately 2-4 hours before the procedure. Patients will be monitored preoperatively for known side effects such as nausea, vomiting, hypotension, and photosensitivity.\n\nThe surgical procedure will follow standard robotic partial nephrectomy techniques, with the addition of fluorescence imaging. Surgeons will first visualize the exposed tumor under white light and capture images. The operative field will then be examined using a specially modified blue-light imaging system to determine whether the tumor exhibits fluorescence. Following tumor excision under standard white light, the resection bed will again be examined with blue light to identify any residual fluorescent tissue that may indicate remaining tumor. If concerning fluorescence is observed, additional tissue margins may be resected and sent separately for pathological examination.\n\nThe primary outcomes include the ability of blue-light fluorescence imaging to detect kidney tumors and assist in evaluating residual disease. Investigators will compare tumor detection under white light versus blue light and calculate sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) using final surgical pathology as the gold standard. Receiver operating characteristic (ROC) curve analysis will be used to compare diagnostic performance between imaging modalities.\n\nThis proof-of-concept study seeks to determine whether 5-ALA fluorescence-guided surgery can improve intraoperative visualization of kidney tumors while maintaining an acceptable safety profile. Positive findings could support larger studies and potentially justify advancement to a Phase III clinical trial investigating fluorescence-guided kidney cancer surgery.",[32],{"label":33,"type":34,"description":35,"interventionNames":36},"5-ALA Fluorescence Imaging","EXPERIMENTAL","Participants will receive a single oral dose of 5-aminolevulinic acid (5-ALA, Gleolan) 2-4 hours prior to ureteroscopic tumor resection. Blue light endoscopy will be used intraoperatively to assess tumor fluorescence and aid in visualization and resection.",[37],"Drug: 5-Aminolevulinic acid Hydrochloride (Gliolan®)",[39],{"type":40,"name":41,"description":42,"armGroupLabels":43,"otherNames":44},"DRUG","5-Aminolevulinic acid Hydrochloride (Gliolan®)","Participants will receive a single oral dose of 5-aminolevulinic acid (20 mg\u002Fkg) approximately 2 to 4 hours prior to surgery. The goal is to evaluate the feasibility of using fluorescence cystoscopy with blue light to improve tumor detection and visualization during ureteroscopic resection of upper tract urothelial carcinoma.\n\nOther Name:",[33],[45,46],"Gleolan","5-ALA",[48],{"name":49,"affiliation":50,"role":51},"Johar Raza, MD","Henry Ford Health","PRINCIPAL_INVESTIGATOR",[53],{"name":54,"role":55,"phone":56,"phoneExt":26,"email":57},"Peace Deh, MD","CONTACT","313-916-7699","pdeh1@hfhs.org",[59],{"facility":50,"status":60,"city":61,"state":62,"zip":63,"country":64,"countryCode":65,"cosmosGeoPoint":66,"geoPoint":71,"contacts":72},"RECRUITING","Detroit","Michigan","48202","United States","US",{"type":67,"coordinates":68},"Point",[69,70],-83.04575,42.33143,{"lat":70,"lon":69},[73],{"name":49,"role":55,"phone":74,"phoneExt":26,"email":75},"313-585-0578","jraza1@hfhs.org",{"type":51,"investigatorFullName":77,"investigatorTitle":78,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"Johar Raza","Urologic Oncologist, Henry Ford Health","100656611","phase-2-photodynamic-diagnosis-of-kidney-cancer-using-fluorescence-endoscopy-and-oral-5-ala-100656611",false,"NCT07828704","Photodynamic Diagnosis of Kidney Cancer Using Fluorescence Endoscopy and Oral 5-ALA","A Phase II Study on Photodynamic Diagnosis of Urological Cancer in the Kidney Using Fluorescence Endoscopy With Cystoscopy and Ureteroscopy With 5-ALA","Inclusion Criteria:\n\n* Patients aged 18 or older\n* Has indications for standard-of-care partial nephrectomy\n* Able to provide informed consent\n* Able to comply with study requirements\n\nExclusion Criteria:\n\n* Known porphyria or hypersensitivity to porphyrins\n* Pregnant or breastfeeding women\n* AST or ALT \\> 2x upper limit of normal within 30 days prior to surgery\n* Participation in another investigational study within 30 days\n* Known allergy or contraindication to 5-ALA or its components","ALL","18 Years","75 Years",{"count":90,"type":91},10,"ESTIMATED","INTERVENTIONAL",[94],"PHASE2","The goal of this prospective, single-arm feasibility study is to evaluate the safety and feasibility of using Gleolan® (5-aminolevulinic acid), an FDA-approved drug currently used during brain tumor surgery, in adults with suspected kidney cancer undergoing partial nephrectomy. Gleolan has shown promise in improving the visualization of cancerous tissue, and this study aims to assess its potential use in urologic oncology. The main questions it aims to answer are:\n\n* Is Gleolan safe and well tolerated in patients with suspected kidney cancer undergoing partial nephrectomy?\n* Is the use of Gleolan feasible for fluorescence-guided identification of kidney cancer lesions during surgery?\n\nParticipants will:\n\n* Receive Gleolan before surgery according to the study protocol.\n* Undergo partial nephrectomy, during which fluorescence imaging will be used to evaluate the visualization of kidney tumor tissue.\n* Be monitored for safety outcomes and any adverse events before, during, and after surgery.",[97],"Kidney Cancers",[99,45,100,101,102,103,104,105,106,107],"5-Aminolevulinic Acid (5-ALA)","Kidney Cancer","Partial Nephrectomy","Photodynamic Diagnosis","Fluorescence-Guided Surgery","Renal Cell Carcinoma","Minimally Invasive Surgery","Urologic Oncology","Blue Light","2026-09-15",{"date":110,"type":111},"2026-09-18","ACTUAL",{"date":108,"type":91},{"date":114,"type":91},"2028-01",{"name":5,"class":6},1]